Q2 2025 Bio-Techne Corp Earnings Call Transcript
Key Points
- Bio-Techne Corp (TECH) reported a strong fiscal quarter with 9% organic revenue growth, exceeding initial projections.
- The company saw a significant increase in adjusted operating margin, up 110 basis points sequentially to 30.1%.
- Sales to biopharma end markets increased mid-teens, driven by strong demand from large pharma customers.
- The company's GMP reagents revenue increased over 90%, indicating robust growth in the cell therapy sector.
- Bio-Techne Corp (TECH) expanded its geographic reach through new distribution agreements in the Gulf countries, Turkey, and Azerbaijan.
- Sales in China declined low single digits due to a challenging economic environment, impacting overall growth.
- The diagnostics and spatial biology segment's operating margin decreased compared to the prior year, partly due to incentive compensation accruals.
- The company faces a headwind of approximately 1% of sales in the second half of the fiscal year due to the strengthening of the US dollar.
- There is uncertainty regarding the timing of large GMP protein orders, which can lead to volatility in quarterly growth.
- Concerns around NIH funding and its potential impact on the academic market were noted, although no immediate effects were observed.
Good morning, and welcome to the Bio-Techne conference call for the second quarter of fiscal year 2025. (Operator Instructions) I would now like to turn the call over to David Clair, Bio-Techne's Vice President, Investor Relations.
Good morning, and thank you for joining us. On the call with me this morning are Kim Kelderman, President and Chief Executive Officer; and Jim Hippel, Chief Financial Officer of Bio-Techne.
Before we begin, let me briefly cover our Safe Harbor statement. Some of the comments made during this conference call may be consider ward-looking statements, including beliefs and expectations about the company's future results. The company's 10-K for fiscal year 2024 identify certain is that could cause the company's actual results to differ materially from those projected in the forward-looking statements made during this call.
The company does not undertake to update any forward-looking statements because of any new information or future events or developments. The 10-K as
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
